ADial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment or prevention of addiction and related disorders. Co.'s investigational new drug product, AD04, is being developed as a therapeutic agent for the treatment of alcohol use disorder. Co. has a license from the University of Virginia Patent Foundation to commercialize its AD04. The active pharmaceutical agent in AD04, Co.'s investigational new drug product, is ondansetron, which is also the active ingredient in Zofran®, an approval for nausea and vomiting post-operatively and after chemotherapy or radiation treatment and is commercially available in generic form. The ADIL stock yearly return is shown above.
The yearly return on the ADIL stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the ADIL annual return calculation with any dividends reinvested as applicable (on ex-dates).
|